TITLE

FDA APPROVES CEPHALON TREANDA TO TREAT NON-HODGKINS LYMPHOMA

PUB. DATE
December 2008
SOURCE
Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the Treanda, bendamustine hydrochloride, from Cephalon Inc. by the U.S. Food and Drug Administration (FDA). The injectable drug is intended for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that progressed during treatment with rituximab or a rituximab-containing regimen. Data showed that the drug is effective and has a tolerable side effect among patients.
ACCESSION #
35409955

 

Related Articles

  • Cephalon wins FDA approval for lymphoma drug.  // PharmaWatch: Biotechnology;Dec2008, Vol. 7 Issue 12, p12 

    The article reports on the approval that the U.S. Food and Drug Administration (FDA) granted to Cephalon Inc.'s Treanda for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a...

  • FDA accepts Cephalon's NDA for lymphoma drug.  // PharmaWatch: Biotechnology;Apr2008, Vol. 7 Issue 4, p10 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) of Cephalon Inc. for its Treanda, a drug for treating patients with indolent B-cell non-Hodgkin's lymphoma (NHL). It was that FDA accepted Cephalon's NDA after the drug successfully...

  • New molecular entity: Treanda.  // Formulary;May2008, Vol. 43 Issue 5, p156 

    The article reports on the approval given to bendamustine, an alkylating agent, from Cephalon Inc. by the U.S. Food and Drug Administration. The drug was approved on March 20, 2008 for the treatment of chronic lymphocytic leukemia (CLL). The efficacy of bendamustine was evaluated in a...

  • FDA Gives Thumbs Down to Nuvigil for Jet Lag.  // Bioworld Week;1/3/2011, Vol. 19 Issue 1, p3 

    The article reports on the disapproval of the U.S. Food and Drug Administration (FDA) to the sleep disorder drug Nuvigil of Cephalon Inc. to be medicated for jet lag.

  • Cell Therapeutics: pixantrone steps closer to FDA approval.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p11 

    In this article, the author discusses a Phase III trial which suggests that pixantrone could treat non-Hodgkin's lymphoma. The author says that the study strengthens the case for the drug's approval by the U.S. Food and Drug Administration (FDA), but Cell Therapeutics Inc., the manufacturer, may...

  • FDA approves lenalidomide for treatment of mantle cell lymphoma.  // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p9 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the immunomodulating agent lenalidomide for the treatment of mantle cell lymphoma.

  • FDA APPROVES TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA.  // Medical Economics;3/10/2014, Vol. 91 Issue 5, p12 

    The article reports on accelerated approval granted by the U.S. Food and Drug Administration to Imbruvica to treat mantle cell lymphoma if patients had received one prior therapy.

  • Recent Cancer Drugs Approved by the FDA.  // Journal of Hematology Oncology Pharmacy;Sep2014, Vol. 4 Issue 3, p28 

    The article presents updates on drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of various types of cancer. These include the use of pembrolizumab for the treatment of patients with unresectable or metastatic melanoma and disease progression after therapy with...

  • TreatmentUpdate.  // McKnight's Long-Term Care News;Sep2013, Vol. 34 Issue 9, p8 

    The article offers news briefs related to the long term care industry in the U.S. as of September 2013 including the efficacy of the drug Grafix from Osiris Therapeutics Inc. and warning from the U.S. Food and Drug Administration related to unapproved drugs to treat diabetes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics